IPSEN (OTCMKTS:IPSEY) Sees Large Volume Increase – Still a Buy?

Shares of IPSEN (OTCMKTS:IPSEY) saw strong trading volume on Monday . 1,039 shares were traded during mid-day trading, an increase of 104% from the previous session’s volume of 510 shares.The stock last traded at $37.57 and had previously closed at $36.80.

Analyst Ratings Changes

IPSEY has been the topic of a number of research analyst reports. UBS Group downgraded IPSEN from a “strong-buy” rating to a “hold” rating in a research note on Thursday. BNP Paribas lowered IPSEN to an “underperform” rating in a report on Wednesday, November 26th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, IPSEN has an average rating of “Hold”.

IPSEN Trading Up 2.1%

The firm has a fifty day simple moving average of $35.95 and a two-hundred day simple moving average of $33.92.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).